Indication
Type 1 Diabetes Mellitus With Diabetic Nephropathy
1 clinical trial
3 products
Clinical trial
Individual and Combined Endothelin Receptor and SGLT1/2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter, Open-label Randomized Cross-over TrialStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Product
SotagliflozinProduct
AmbrisentanProduct
Ambrisentan + Sotagliflozin